Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
186 hedge funds and large institutions have $2.05B invested in Acorda Therapeutics in 2015 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 67 increasing their positions, 70 reducing their positions, and 17 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
68% more capital invested
Capital invested by funds: $1.23B → $2.05B (+$829M)
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
6% more funds holding
Funds holding: 176 → 186 (+10)
4% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 70
26% less call options, than puts
Call options by funds: $10.2M | Put options by funds: $13.8M
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$90.4M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$50.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.6M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$13.6M |
| 5 |
Jennison Associates
New York
|
+$12.1M |
Top Sellers
| 1 |
UBS AM
Chicago,
Illinois
|
-$67.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$33.9M |
| 3 |
Millennium Management
New York
|
-$11.9M |
| 4 |
Barclays
London,
United Kingdom
|
-$9.07M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$8.92M |
ACOR Hedge Fund Activity: Q4 2015 in Review
186 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2015, worth a combined $2.05B — up 68% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACOR positions and 17 closed out — a net gain of 11 holders — while 67 added to existing stakes and 70 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $90.4M. The largest seller was UBS AM, cutting an estimated $67.7M.
- 186 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2015, up from 176 in Q3 2015.
- Funds reported $2.05B of Acorda Therapeutics stock for Q4 2015, up 68% quarter-over-quarter.
- 28 funds opened new Acorda Therapeutics positions in Q4 2015 and 17 closed out, a net change of +11 holders.
- The largest Acorda Therapeutics buyer in Q4 2015 was Baker Bros. Advisors, an estimated $90.4M added.
- The largest Acorda Therapeutics seller in Q4 2015 was UBS AM, an estimated $67.7M sold.
Based on aggregated 13F filings for Q4 2015.